Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

ClinicalTrials.gov ID: NCT01583543

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01583543. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.

Study identification

NCT ID: NCT01583543
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Massachusetts General Hospital; Other
Enrollment: 12 participants

Conditions and interventions

Conditions

Ewing's Sarcoma

Interventions

Olaparib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2012 (Type not available)
Primary completion: Jan 2014 (Actual)
Completion: Nov 2014 (Actual)
Last update posted: May 19, 2017

2012 – 2014

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Massachusetts General Hospital	Boston	Massachusetts	02115	—
Brigham and Women's Hospital	Boston	Massachusetts	02215	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01583543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 19, 2017 · Synced Nov 15, 2026